Bumetanide

Catalog No.

A1855

NKCC cotransporter inhibitor

Grouped product items
Size	Price	Stock
10mM (in 1mL DMSO)	$94.00	Please inquire
1g	$88.00	Please inquire
5g	$352.00	Please inquire

For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Background

Loop diuretic that inhibits the Na⁺/2Cl^-/K⁺ (NKCC) cotransporter. More potent than furosemide.

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	364.42
Cas No.	28395-03-1
Formula	C₁₇H₂₀N₂O₅S
Solubility	insoluble in H2O; ≥36.37 mg/mL in DMSO; ≥4.04 mg/mL in EtOH
Chemical Name	3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
SDF	Download SDF
Canonical SMILES	CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Cell experiment:[1]
Cell lines	NKCC1A-expressing Xenopus oocytes
Reaction Conditions	0.03 ~ 100 μM bumetanide for 5 min incubation
Applications	Bumetanide inhibited the ⁸⁶Rb⁺ uptake in NKCC1A-expressing oocytes in a dose-dependent manner. At the doses ranging from 30 to 100 μM, bumetanide reduced the ⁸⁶Rb⁺ uptake to background levels.
Animal experiment:[2]
Animal models	Dogs
Dosage form	0.1 mg/kg Injected intravenously
Applications	Bumetanide (0.1 mg/kg) significantly increased urine flow and sodium and potassium excretion, as well as decreased sodium reabsorption, in anesthetized dogs. In addition, bumetanide was approximately 30-fold more potent than furosemide in enhancing sodium excretion.
Note	The technical data provided above is for reference only.
	References: 1. Lykke K, T?llner K, Feit PW, et al. The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A. Epilepsy & Behavior, 2016, 59: 42-49. 2. Cohen MR, Hinsch E, Vergona R, et al. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog. Journal of Pharmacology and Experimental Therapeutics, 1976, 197(3): 697-702.

Purity = 99.82%